The science behind rare disease treatments is advancing at a rapid rate, with the focus of attention to the patient's needs. The company is focusing on ensuring next-generation therapies deliver greater efficacy and durability for patients. The CEO of the company, however, also discusses the rapidly evolving regulatory environment.